MedPath

Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients

Phase 1
Conditions
COVID
Sars-CoV2
Coronavirus Infection
Interventions
Other: Injectable Placebo
Drug: Placebo empty capsule
Registration Number
NCT04472585
Lead Sponsor
Sohaib Ashraf
Brief Summary

To measure the effect of Ivermectin (sub-cutaneous) with or without zinc in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.

Detailed Description

This is a parallel assigned, randomized, controlled, multi-armed, investigator Initiated interventional study is designed to demonstrate efficacy to lower the viral load of COVID-19 and to demonstrate the antiviral effects of subcutaneous Ivermectin with or without zinc in mild to moderate symptomatic patients who consent to randomization following a new diagnosis in Pakistan with COVID-19 (PCR positive). Investigators will follow up with participants daily and PCR will be done on alternate days in BSL-3 lab. Dose will only be repeated if test remained positive..

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
180
Inclusion Criteria
  • Nasopharyngeal RT-PCR positive SARS-CoV-2 patient with mild to moderate disease
  • Age 18 and above
  • BMI 18-28 kg/m
Exclusion Criteria
  • Allergy to any drug
  • Co-morbidities: any pre-existing cardiac disease, pulmonary disease
  • Arrhythmias
  • Pregnancy
  • RT-PCR performed >3 days prior to enrollment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ivermectin with ZincIvermectin Injectable SolutionSub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly with 20mg Zinc Sulphate 8 hourly plus standard care
Ivermectin alonePlacebo empty capsuleSub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly plus standard care
Ivermectin (oral) aloneOral IvermectinOral ivermectin 0.2mg/kg/day
PlaceboInjectable PlaceboPlacebo drug plus standard care
Ivermectin with ZincPlacebo empty capsuleSub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly with 20mg Zinc Sulphate 8 hourly plus standard care
Zinc AlonePlacebo empty capsule20mg Zinc Sulphate 8 hourly plus standard care
Ivermectin aloneIvermectin Injectable SolutionSub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly plus standard care
PlaceboPlacebo empty capsulePlacebo drug plus standard care
Ivermectin (oral) alonePlacebo empty capsuleOral ivermectin 0.2mg/kg/day
Ivermectin (oral) with ZincPlacebo empty capsuleOral ivermectin 0.2mg/kg/day with 20mg Zinc Sulphate 8 hourly plus standard care
Ivermectin (oral) with ZincOral IvermectinOral ivermectin 0.2mg/kg/day with 20mg Zinc Sulphate 8 hourly plus standard care
Ivermectin with ZincZincSub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly with 20mg Zinc Sulphate 8 hourly plus standard care
Ivermectin (oral) with ZincZincOral ivermectin 0.2mg/kg/day with 20mg Zinc Sulphate 8 hourly plus standard care
Zinc AloneZinc20mg Zinc Sulphate 8 hourly plus standard care
Primary Outcome Measures
NameTimeMethod
qRT-PCR14 days

time needed to turn positive COVID-19 PCR to negative

Time taken for alleviation of symptomsupto 14 days

time needed to turn off symptoms

Severity of symptomsupto 14 days

time needed of symptom serverity

Secondary Outcome Measures
NameTimeMethod
Severity of symptoms14 days

time needed to make patients clinically better

Morality30 days

death rate

Trial Locations

Locations (2)

Ali Clinic

🇵🇰

Lahore, MA, Pakistan

Shaikh Zayed Hospital

🇵🇰

Lahore, Punjab, Pakistan

© Copyright 2025. All Rights Reserved by MedPath